Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

17-06-2021 | ASCO 2021 | Conference coverage | Video

INDUCE-1 points to ICOS agonist activity in advanced urothelial cancer

Arjun Balar talks through the INDUCE-1 trial findings for patients with advanced urothelial carcinoma who were given the ICOS agonist feladilimab alone or alongside pembrolizuamb (6:39).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

14-06-2021 | ASCO 2021 | Conference coverage | Video

Pembrolizumab benefit confirmed for cisplatin-ineligible advanced UC patients

25-09-2020 | ESMO 2020 | Conference coverage | Video

First-line pembrolizumab combination fails to boost advanced urothelial cancer survival

14-06-2017 | Urothelial cancer | Conference coverage | News

First-line pembrolizumab feasible for cisplatin-ineligible advanced urothelial cancer patients
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits